ASX News

Telix Granted FDA Orphan Drug Designation for Glioma Imaging Agent

Melbourne (Australia) – 6th October 2020. Telix Pannounces FDA has granted Orphan Drug Designation (ODD) for O-(2-[18F]fluoroethyl)-L-tyrosine for PET imaging of glioma

Telix Pharmaceuticals Limited is pleased to announce that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for O-(2-[18F]fluoroethyl)-L-tyrosine (18F-FET), for the positron emission tomography (PET) imaging of glioma, a type of brain tumour.

The granting of an ODD for 18F-FET qualifies Telix for various drug development incentives which may include FDA-administered market exclusivity for seven years, waived FDA prescription drug user fees, and tax credits for R&D and clinical development costs.

Telix CEO Dr Christian Behrenbruch said,
“PET imaging of the brain is increasingly used to supplement conventional imaging with MRI, which for many years has been the primary clinical imaging modality in patients with glioma at all stages of disease. The granting of an Orphan Drug Designation by the FDA for 18F-FET provides Telix with the option to develop this valuable PET imaging agent commercially, to ensure it is available to patients with glioma across the disease spectrum. 18F-FET’s relevance as a patient selection and therapeutic monitoring tool for TLX101 is particularly beneficial to the Company”

To read full ASX release please click here.

More Articles

Corporate Spotlight

First Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product in Turkey

Melbourne (Australia) and Istanbul (Turkey) – 22nd October 2020. Telix and Eczacıbaşı-Monrol Nuclear Products Co. are pleased to announce that...

Corporate Spotlight

Telix Pharmaceuticals to Participate at AusBiotech + Invest 2020

12th October 2020 – Corporate Spotlight | Telix Pharmaceuticals will participate in AusBiotech + Invest 2020

Corporate Spotlight

Telix to Present at European Association of Nuclear Medicine 2020 Annual Congress

12th October 2020 – Clinical Spotlight | Telix to Present at European Association of Nuclear Medicine 2020 Virtual Conference

ASX News

Telix Granted FDA Orphan Drug Designation for Glioma Imaging Agent

Melbourne (Australia) – 6th October 2020. Telix Pannounces FDA has granted Orphan Drug Designation (ODD) for O-(2-[18F]fluoroethyl)-L-tyrosine for PET imaging...

ASX News

Telix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product

Melbourne (Australia) and Indianapolis (U.S.A.) – 24th September 2020. Telix Pharmaceuticals submits NDA to US FDA for TLX591-CDx (Kit for...

ASX News

First Patients Dosed in Clinical Trial of Novel Lung and Ovarian Cancer Theranostic

Melbourne and Adelaide (Australia) – 21st September 2020. Telix announces first two patients dosed in phase I trial of lung...

ASX News

Telix Pharmaceuticals Enters Strategic Collaboration with Varian Medical Systems for Advanced Prostate Imaging

Melbourne (Australia) and Palo Alto, CA (USA) – 3rd September 2020. Telix announces it has entered into a strategic collaboration...

ASX News

Telix Pharmaceuticals and IRE Elit Enter Distribution Partnership for Prostate Cancer Imaging

Herstal and Fleurus (Belgium) – 1st September 2020. Telix announces distribution agreement with Fleurus-based IRE Elit S.A. to distribute Telix’s...

ASX News

FDA Grants Orphan Drug Designation for TLX102

Melbourne (Australia) – 31st August 2020. Telix announces the FDA has granted ODD for 4-[211At] astato-l-phenylalanine for the treatment of...

ASX News

Half Year Shareholder Update

Melbourne (Australia) – 21st August 2020. Telix Pharmaceuticals Limited Announces Half-year Shareholder Update

ASX News

First patient dosed in renal cancer imaging study in Japan

Melbourne (Australia) – 18th August 2020. Telix announces the first patient has been dosed in a Phase I/II study of...

ASX News

Drug Master File for Glioblastoma Therapy Product Filed with FDA

Melbourne (Australia) and Indianapolis, IN (USA) – 11th August 2020. Telix announces it has submitted a Drug Master File to...

ASX News

Completion of Phase I Enrolment of Japanese Renal Cancer Study

Tokyo (Japan) – 27th October 2020. Telix Pharmaceuticals Japan K.K. is pleased to announce the completion of Phase I enrolment...